Read the latest news about Make 2nds Count and secondary breast cancer. 

For press enquiries, contact Katie or Cristina at Four Marketing Agency, Tel 07809 547426 / 07900 640819

Keep up-to-date with the latest news by signing up to our news bulletin and by following us on Twitter  and Instagram.



Instagram Post 13
27th March 2024

Make 2nds Count Joins Drug Consultation Process for Elacestrant

In a first for the charity, we are working with the National Institute for Health and Care Excellence (NICE) as a stakeholder in the drug consultation process for a new treatment for secondary breast cancer called Elacestrant. Elacestrant is currently approved to treat people in the EU and USA living with oestrogen receptor-positive (HR+) HER2-negative (HER2-) secondary breast cancer with an ESR1 mutation, who experience disease progression after at least one line of hormone therapy.

Read more 
M2C 05
13th March 2024

500 Secondary Breast Cancer Patients Supported by Patient Trials Advocate Service

The Make 2nds Count Patient Trials Advocate (PTA) service has so far supported 500 secondary breast cancer patients across the UK, marking a significant milestone and pivotal achievement in advancing patient access to clinical trials. The PTA service is the first of its kind in the UK, offering fresh hope to patients by connecting them with clinical trials that have the potential to improve outcomes and extend life.

Read more 
Instagram Post 11 v3
12th March 2024

Medicine for rare form of breast cancer approved for use on the NHS in Scotland

Make 2nds Count is pleased to hear from the Scottish Medicines Consortium (SMC) that Talazoparib (Talzenna) has been approved to treat adults with BRCA1 or 2 mutated HER2-negative secondary breast cancer. The announcement is welcome news for many people in Scotland and their families as this is the first ever BRCA-targeted treatment for those living with locally advanced or secondary breast cancer.

Read more  treatments